Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
Details for Australian Patent Application No. 2005226736 (hide)
International Classifications
Event Publications
19 October 2006 PCT application entered the National Phase
PCT publication WO2005/092073 Priority application(s): WO2005/092073
4 June 2009 Assignment before Grant
PDL BioPharma, Inc. The application has been assigned to Facet Biotech Corporation
26 November 2009 Application Accepted
Published as AU-B-2005226736
25 March 2010 Standard Patent Sealed
27 January 2011 Alteration of Name
The name of the patentee has been altered to Abbott Biotherapeutics Corp.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2005226741-Acrylonitrile derivatives for inflammation and immune-related uses
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser